TG Therapeutics, Inc. TGTX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing novel therapies for B‑cell mediated diseases. The company’s primary commercial product is BRIUMVI, an anti‑CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis, addressing…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees374
TickerTGTX
Statistics
Market Cap$7.88B
Revenue (TTM)$616.3M
Net Income$447.2M
Net Margin72.6%
EPS$2.77
P/E16.80
P/S10.50
P/B11.68
EV/EBITDA45.77
ROE112.6%
Dividend Yield—
Price$51.48
Data: Twelve Data · Revenue = mcap / P/S